Startup entity

Biotech Startups

industry

regulation is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention FDA, the most common co-covered peer. Source depth averages 3.5 original sources per story, versus 3.2 across the same-window beat baseline.

Last mentioned: Feb 24, 2026

Entity pulse

Recent coverage · Biotech Startups

2 stories
7.5 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Biotech Startups

regulation is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention FDA, the most common co-covered peer. Source depth averages 3.5 original sources per story, versus 3.2 across the same-window beat baseline. The 7.5 average consequence score is above the beat benchmark of 6.7 in the same window. This profile follows 2 Startup stories mentioning Biotech Startups across the period from February 24, 2026 to February 26, 2026.

Stories tracked
2
Sources per story
3.5

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 104 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Biotech Startups. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Biotech Startups 2

Policy Positive

FDA to Incentivize Faster Drug Reviews with New Staff Bonus Program

The U.S. Food and Drug Administration is introducing a performance-based bonus system to reward staffers who complete drug reviews ahead of schedule. This regulatory shift aims to clear backlogs and could significantly shorten the path to market for biotech startups and their venture backers.

5 sources
Policy Positive

FDA Unveils Regulatory Framework for Bespoke Rare Disease Therapies

The FDA has proposed a groundbreaking regulatory system designed to streamline the approval of customized, 'N-of-1' therapies for ultra-rare diseases. This shift marks a transition from traditional mass-market drug evaluation to a platform-based approach, potentially unlocking significant venture investment in precision medicine.

2 sources

Biotech Startups is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.